BioAge Labs, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIOA Nasdaq 2836 bioagelabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioAge Labs, Inc.

BioAge Labs to Present at Upcoming Investor Conferences - May 22nd, 2026 7:00 am
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - May 20th, 2026 2:43 pm
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday - May 13th, 2026 11:43 am
AMD, Under Armour downgraded: Wall Street's top analyst calls - May 13th, 2026 7:35 am
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - May 13th, 2026 6:47 am
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More - May 13th, 2026 5:54 am
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - May 8th, 2026 1:12 pm
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - May 8th, 2026 7:00 am
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - May 4th, 2026 2:30 pm
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - Apr 24th, 2026 10:43 am
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year? - Apr 23rd, 2026 7:40 am
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - Apr 21st, 2026 7:55 am
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug - Apr 21st, 2026 5:19 am
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP - Apr 21st, 2026 5:00 am
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference - Apr 16th, 2026 5:03 pm
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - Apr 13th, 2026 2:30 pm
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Apr 7th, 2026 8:00 am
BGE-102 Data Inspires Confidence for BioAge Labs (BIOA) - Mar 31st, 2026 5:34 am
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 - Mar 24th, 2026 7:00 am
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress - Mar 23rd, 2026 1:50 am